Vedanta Biosciences Announces Successful Phase 1a/1b Data for Lead, Rationally Defined Bacterial Consortium Product Candidate
Vedanta Biosciences announced preliminary results from the Phase 1a/1b clinical study in healthy volunteers for its lead, orally-administered live biotherapeutic product (LBP) candidate for recurrent Clostridium difficile infection (rCDI), VE303. With these Phase 1 data […]